

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

NCT07491913

Status	RECRUITING
Phase	Not Applicable
Sponsor	Marmara University
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (6)

- Diagnosis of Takayasu arteritis according to the 2022 American College of Rheumatology/EULAR classification criteria
- Treatment with biologic therapy (TNF inhibitors or tocilizumab) for at least 3 years
- Sustained clinical, laboratory, and radiologic remission
- No change in treatment during the previous 12 months
- No glucocorticoid use within the previous 6 months
- ... and 1 more (see full listing online)

Exclusion (3)

- Presence of other active inflammatory diseases requiring biologic therapy (e.g., inflammatory bowel disease, ankylosing spondylitis)
- Inability to attend scheduled follow-up visits after treatment tapering and discontinuation
- Pregnancy or planning pregnancy during the study period

Locations (1 total)

Marmara University Pendik Training and Research Hospital, Istanbul, Turkey (Türkiye)